Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention?

Bryce M. Churilla; Faten Aqeel; Antoine Azar; Brendan Antiochos; Philip Seo; David B. Hellmann; Duvuru Geetha

doi:10.1016/j.kint.2022.04.035

Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention?

Bryce M. Churilla, Faten Aqeel, Antoine Azar, Brendan Antiochos, Philip Seo, David B. Hellmann, Duvuru Geetha

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	444-445
Number of pages	2
Journal	Kidney international
Volume	102
Issue number	2
DOIs	https://doi.org/10.1016/j.kint.2022.04.035
State	Published - Aug 2022

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.kint.2022.04.035

Cite this

@article{5eb7950f48c54332840c15bb040df04f,

title = "Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention?",

author = "Churilla, {Bryce M.} and Faten Aqeel and Antoine Azar and Brendan Antiochos and Philip Seo and Hellmann, {David B.} and Duvuru Geetha",

note = "Funding Information: DG is supported by the Johns Hopkins Center of Innovative Medicine and Jerome L Greene Discovery Award.",

year = "2022",

month = aug,

doi = "10.1016/j.kint.2022.04.035",

language = "English (US)",

volume = "102",

pages = "444--445",

journal = "Kidney international",

issn = "0085-2538",